

U.S. Nasal Polyps Treatment Market - 2025 -2033

<https://marketpublishers.com/r/UB7E242129F7EN.html>

Date: October 2025

Pages: 180

Price: US\$ 3,175.00 (Single User License)

ID: UB7E242129F7EN

Abstracts

U.S. Nasal Polyps Treatment Market Size

In 2023, the U.S. Nasal Polyps Treatment Market was valued at US\$ 2.9 Billion. The U.S. Nasal Polyps Treatment Market size reached US\$ 3.06 Billion in 2024 and is expected to reach US\$ 5.12 Billion by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033.

U.S. Nasal Polyps Treatment Market Overview

The U.S. nasal polyps treatment market is poised for significant growth, driven by a combination of increasing disease prevalence, advancements in treatment options, and improved diagnostic rates. As awareness of the condition rises and more patients seek medical intervention, the demand for effective, long-term treatment solutions continues to grow.

A key catalyst for market expansion is the emergence of biologic therapies that offer targeted, disease-modifying effects. Unlike conventional treatments such as corticosteroids and surgery, biologics address the underlying inflammatory pathways responsible for nasal polyps, providing sustained symptom relief and reducing recurrence. The development and approval of new biologics, particularly monoclonal antibodies targeting interleukins, are expected to reshape the treatment landscape and present lucrative opportunities for pharmaceutical companies.

Overall, with strong clinical pipelines, supportive reimbursement frameworks, and a shift toward personalized medicine, the U.S. nasal polyps market is well-positioned for dynamic growth during the forecast period.

U.S. Nasal Polyps Treatment Market Dynamics: Drivers & Restraints

Drivers:

Rising prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) is significantly driving the U.S. nasal polyps treatment market growth

The rising prevalence of nasal polyps in the United States is a key factor propelling the growth of the nasal polyps treatment market. For instance, according to the Allergy & Asthma Network, the nasal polyps affect 4% of the U.S. population. Additionally, according to the National Institute of Health report in 2025, it is stated that in the United States, prevalence estimates for nasal polyps vary. Approximately 2.1% of individuals meet the diagnostic criteria for CRSwNP based on the presence of two major symptoms, while about 13.0% report experiencing just one symptom.

Among all patients diagnosed with chronic rhinosinusitis (CRS), an estimated 25% to 30% are further classified as having CRSwNP. The condition most commonly develops between the ages of 40 and 60. This growing patient pool is accelerating the demand for advanced therapies, especially biologics like Dupixent and Xolair, which offer targeted treatment for patients who do not respond well to corticosteroids or surgery.

The surge in cases is also encouraging pharmaceutical companies to invest more in R&D and expand their biologic pipelines, further contributing to market expansion and innovation.

Restraint:

The high cost of biologic treatments is hampering the growth of the U.S. Nasal Polyps Treatment market

A limited number of approved drugs presents a notable challenge to the growth and diversity of the U.S. nasal polyps treatment market. Currently, only a few FDA-approved biologics are available, namely Dupixent, Xolair, and Nucala, which restricts therapeutic choices for both patients and healthcare providers. This is especially concerning for individuals who do not respond well to these treatments or who experience side effects.

With all approved therapies targeting similar inflammatory pathways like IL4, IL5, or IgE, the potential for personalized treatment approaches remains limited. The high cost of these biologics, combined with a lack of alternative options, also adds pressure to insurance systems and makes access difficult for many patients, ultimately reducing

broader adoption.

For instance, the current annual list price of XOLAIR ranges from approximately \$30,000 to \$60,000, depending on dosage and treatment regimen.

Opportunity:

Pipeline development of new biologics is expected to create a lucrative opportunity for the growth of the U.S. nasal polyps treatment market

The pipeline development of new biologics presents a significant opportunity for the U.S. nasal polyps treatment market, primarily by addressing limitations in current therapies and targeting the underlying causes of the condition.

Biologics offer targeted, long-acting relief by modulating key inflammatory pathways involved in chronic rhinosinusitis with nasal polyps (CRSwNP), such as IL-4, IL-5, and IL-13. As more biologics advance through clinical trials, they hold the potential to dramatically reduce recurrence rates, delay or eliminate the need for repeated surgeries, and improve quality of life for patients with moderate-to-severe disease.

Additionally, the increasing focus on personalized medicine, expanding clinical evidence, and growing insurance coverage for biologic therapies are expected to further drive their adoption, making this an attractive and high-growth segment within the U.S. nasal polyps market.

U.S. Nasal Polyps Treatment Market, Segment Analysis

The U.S. nasal polyps treatment market is segmented based on type, treatment type, and route of administration.

The medication from the treatment type segment are expected to hold 54.25% of the market share in 2024 in the U.S. nasal polyps treatment market

The medication segment is expected to dominate the U.S. nasal polyps market, driven by the increasing adoption of advanced, non-invasive treatments that effectively manage chronic rhinosinusitis with nasal polyps (CRSwNP). Biologic therapies, such as monoclonal antibodies, are transforming disease management by targeting specific inflammatory pathways, offering relief to patients who do not respond to conventional corticosteroids.

There is a growing momentum in the development and approvals of the drugs, which is significantly driving the segment's growth. For instance, in February 2024, the FDA approved an expanded use of Xolair (omalizumab) to help reduce allergic reactions, including nasal polyps, in patients with IgE-mediated food allergies.

This growing integration of novel biologics into clinical practice reflects increasing confidence in targeted therapies and underscores the strong potential of the medication segment to lead the U.S. nasal polyps treatment market.

U.S. Nasal Polyps Treatment Market Competitive Landscape

Top companies in the U.S. nasal polyps treatment market include Sanofi and Regeneron Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, GSK plc., among others.

U.S. Nasal Polyps Treatment Market Key Developments

Regeneron Pharmaceuticals and Sanofi announced that the U.S. FDA approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

DMI Insights

According to DataM Intelligence, the U.S. nasal polyps treatment market is witnessing robust growth driven by a rising burden of chronic rhinosinusitis with nasal polyps (CRSwNP), increasing awareness among patients, and a noticeable shift toward biologic therapies. DMI notes that the emergence of targeted biologics such as monoclonal antibodies is reshaping the treatment landscape, offering more effective and longer-lasting solutions compared to traditional corticosteroids and surgical interventions.

With a strong pipeline of novel therapies under clinical development and expanding reimbursement support, DataM Intelligence expects the market to experience accelerated growth over the forecast period. Furthermore, the growing emphasis on personalized medicine and physician education is expected to improve diagnosis rates and therapeutic outcomes, reinforcing the market's long-term potential.

The U.S. nasal polyps treatment market report delivers a detailed analysis with 60+ key tables, more than 55+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Type
- 2.4. Snippet by Treatment
- 2.5. Snippet by Route of Administration

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
 - 3.1.1.2. Advances in Biologic Therapies
 - 3.1.1.3. Growing Awareness and Diagnosis Rates
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Biologic Treatments
 - 3.1.2.2. Limited Number of Approved Drugs
 - 3.1.2.3. Slow Adoption in Primary Care Settings
 - 3.1.3. Opportunity
 - 3.1.3.1. Pipeline Development of New Biologics
 - 3.1.3.2. Expansion of OTC and Non-Invasive Therapies
 - 3.1.3.3. Strategic Collaborations and Partnerships
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products

- 4.2. Latest Developments and Breakthroughs
- 4.3. Porter's Five Forces Analysis
- 4.4. Supply Chain Analysis
- 4.5. Pipeline Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Pricing Analysis and Price Dynamics

5. U.S. NASAL POLYPS TREATMENT MARKET, BY TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 5.1.2. Market Attractiveness Index, By Type
- 5.2. Ethmoidal*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Antrochoanal

6. U.S. NASAL POLYPS TREATMENT MARKET, BY TREATMENT TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 6.1.2. Market Attractiveness Index, By Treatment type
- 6.2. Medication*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 6.2.3. Corticosteroids
 - 6.2.4. Antibiotics
 - 6.2.5. Leukotriene Inhibitors
- 6.3. Others

7. U.S. NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 7.1.2. Market Attractiveness Index, By Route of Administration

7.2. Nasal*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Oral

7.4. Injectables

8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

8.1. Competitive Overview and Key Market Players

8.2. Market Share Analysis and Positioning Matrix

8.3. Strategic Partnerships, Mergers & Acquisitions

8.4. Key Developments in Product Portfolios and Innovations

8.5. Company Benchmarking

9. COMPANY PROFILES

9.1. Key Players

9.2. Pharming Intellectual Property, B.V.*

9.2.1. Company Overview

9.2.1.1. Product Portfolio

9.2.1.2. Product Description

9.2.1.3. Product Key Performance Indicators (KPIs)

9.2.2. Financial Overview

9.2.2.1. Company Revenue

9.2.2.2. Geographical Revenue Shares

9.2.2.3. Revenue Forecasts

9.2.3. Key Developments

9.2.3.1. Mergers & Acquisitions

9.2.3.2. Key Product Development Activities

9.2.3.3. Regulatory Approvals, etc.

9.2.4. SWOT Analysis

9.3. Novartis Pharmaceuticals Corporation

9.4. GSK plc.

9.5. Emerging Players

9.5.1. AstraZeneca

9.5.2. Eli Lilly and Company

9.5.3. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

9.5.4. Others (LIST NOT EXHAUSTIVE)

10. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 10.1. Data Collection Methods
- 10.2. Data Triangulation
- 10.3. Forecasting Techniques
- 10.4. Data Verification and Validation

11. APPENDIX

- 11.1. About Us and Services
- 11.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 U.S. Nasal Polyps Treatment Market Value, By Type, 2025, 2029 & 2033 (US\$ Billion)

Table 2 U.S. Nasal Polyps Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)

Table 3 U.S. Nasal Polyps Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Billion)

Table 4 U.S. Nasal Polyps Treatment Market Value, By Type, 2025, 2029 & 2033 (US\$ Billion)

Table 5 U.S. Nasal Polyps Treatment Market Value, By Type, 2022-2033 (US\$ Billion)

Table 6 U.S. Nasal Polyps Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)

Table 7 U.S. Nasal Polyps Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 8 U.S. Nasal Polyps Treatment Market Value, By Route of Administration, 2025, 2029 & 2033 (US\$ Billion)

Table 9 U.S. Nasal Polyps Treatment Market Value, By Route of Administration, 2022-2033 (US\$ Billion)

Table 10 Sanofi and Regeneron Pharmaceuticals, Inc.: Overview

Table 11 Sanofi and Regeneron Pharmaceuticals, Inc.: Product Portfolio

Table 12 Sanofi and Regeneron Pharmaceuticals, Inc.: Key Developments

Table 13 Novartis Pharmaceuticals Corporation: Overview

Table 14 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 15 Novartis Pharmaceuticals Corporation: Key Developments

Table 16 GSK plc.: Overview

Table 17 GSK plc.: Product Portfolio

Table 18 GSK plc.: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 2 U.S. Nasal Polyps Treatment Market Share, By Type, 2024 & 2033 (%)

Figure 3 U.S. Nasal Polyps Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 4 U.S. Nasal Polyps Treatment Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 5 U.S. Nasal Polyps Treatment Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 6 Ethmoidal Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 7 Antrochoanal Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 8 U.S. Nasal Polyps Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)

Figure 9 Medication Treatment Type in U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 10 Others Treatment Type in U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 11 U.S. Nasal Polyps Treatment Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 12 Nasal Route of Administration in U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 13 Oral Route of Administration in U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 14 Injectables Route of Administration in U.S. Nasal Polyps Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 15 Sanofi and Regeneron Pharmaceuticals, Inc.: Financials

Figure 16 Novartis Pharmaceuticals Corporation: Financials

Figure 17 GSK plc.: Financials

I would like to order

Product name: U.S. Nasal Polyps Treatment Market - 2025 -2033

Product link: <https://marketpublishers.com/r/UB7E242129F7EN.html>

Price: US\$ 3,175.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UB7E242129F7EN.html>